Such agents in current use include monoclonal antibodies against three key targets: immune checkpoints PD-1 and CTLA-4, which enhance tumor-killing T cell immune functions; pro-angiogenic factor VEGF; and integrin adhesion molecules that mediate interactions between tumor cells and the TME matrix. Here, VEGFA is linked to neoplasm.